Institutional
Rosalind Advisors, Inc.
CIK 0001622627
$248.9M
Reported AUM
38
Positions
Q1 2026
Period
2026-05-14
Filed
The Brief · Rosalind Advisors, Inc. · Q1 2026
AI · grounded in 13F
Rosalind Advisors, Inc. exited its position in REPL for a reduction of $13.7M. The fund also closed positions in ATYR and CYTK, reducing exposure by $13.6M and $12.4M respectively. On the buy side, the fund established a new position in PCVX worth $16.9M and added VOR with a $12.5M investment.
Portfolio · Q1 2026
Top holdings
QoQ vs Q4 2025
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DCTH | DELCATH SYSTEMS, INC. | $10.67 | -1.11% | -34.86% | 4.61% | $30.6M | 12.31% | — | HELD |
| 2 | XERS | XERIS BIOPHARMA HOLDINGS INC | $6.18 | 0.49% | 34.93% | 101.30% | $18.7M | 7.53% | +1,120,000 | +53.0% |
| 3 | FENC | FENNEC PHARMACEUTICALS INC | $8.70 | -5.02% | 3.20% | 33.64% | $17.9M | 7.19% | +294,693 | +11.3% |
| 4 | SVRA | SAVARA INC | $5.09 | -3.96% | 108.61% | 297.66% | $17.5M | 7.03% | −200,000 | −5.9% |
| 5 | PCVX | VAXCYTE INC | $47.36 | -2.87% | 28.03% | 118.45% | $16.9M | 6.77% | +290,000 | NEW |
| 6 | EYPT | EYEPOINT PHARMACEUTICALS INC | $11.78 | -3.92% | 31.77% | 43.31% | $13.4M | 5.37% | +346,737 | +50.3% |
| 7 | XFOR | X4 PHARMACEUTICALS INC | $3.83 | -4.49% | -10.93% | -97.78% | $13.3M | 5.33% | +608,846 | +23.4% |
| 8 | VOR | VOR BIOPHARMA INC | $13.16 | -8.10% | 193.75% | -94.74% | $12.5M | 5.02% | +700,000 | NEW |
| 9 | MDWD | MEDIWOUND LTD | $14.18 | -1.87% | -34.35% | -46.69% | $12.1M | 4.85% | — | HELD |
| 10 | VSTM | VERASTEM INC | $3.71 | -3.89% | -42.21% | -90.43% | $11.3M | 4.55% | +350,000 | +19.6% |
| 11 | CLDX | CELLDEX THERAPEUTICS INC | $28.62 | -4.38% | 34.05% | -34.58% | $10.5M | 4.21% | +330,000 | NEW |
| 12 | BCRX | BIOCRYST PHARMACEUTICALS INC | $8.41 | -0.71% | -23.82% | -47.83% | $8.8M | 3.53% | +923,057 | NEW |
| 13 | HELP | CYBIN INC | $4.15 | -6.32% | -53.37% | -96.42% | $7.4M | 2.95% | −125,726 | −7.6% |
| 14 | CGON | CG ONCOLOGY INC | $53.72 | -4.23% | 99.63% | 20.15% | $6.8M | 2.72% | −200,000 | −66.7% |
| 15 | NSPR | INSPIREMD INC | $0.88 | -5.38% | -64.80% | -76.60% | $6.4M | 2.56% | — | HELD |
| 16 | AVIR | ATEA PHARMACEUTICALS INC | $4.25 | -3.85% | 33.65% | -83.03% | $6.3M | 2.53% | +1,171,855 | NEW |
| 17 | PROF | PROFOUND MEDICAL CORP | $6.66 | -1.91% | 19.57% | -54.38% | $5.4M | 2.16% | −240,837 | −22.5% |
| 18 | VRDN | VIRIDIAN THERAPEUTICS INC | $15.78 | -4.77% | 7.49% | 1.64% | $4.9M | 1.97% | −199,599 | −44.4% |
| 19 | REPL | REPLIMUNE GROUP INC | $9.47 | -4.05% | -8.77% | -71.07% | $2.7M | 1.10% | +1,044,700 | +452.4% |
| 20 | PYPD | POLYPID LTD | $4.50 | -6.83% | 37.61% | -98.16% | $2.6M | 1.05% | −98,630 | −14.2% |
| 21 | MYO | MYOMO INC | $1.28 | -0.78% | -57.05% | -83.00% | $2.6M | 1.04% | +7,500 | +0.2% |
| 22 | TLPH | TALPHERA INC | $0.78 | -2.50% | 51.96% | -96.72% | $2.5M | 1.01% | −225,357 | −6.3% |
| 23 | OVID | OVID THERAPEUTICS INC | $2.40 | -3.23% | 652.35% | -35.66% | $2.5M | 0.99% | +1,107,994 | NEW |
| 24 | DFTX | DEFINIUM THERAPEUTICS INC | $23.55 | -4.23% | 202.31% | -48.69% | $2.4M | 0.95% | +125,000 | NEW |
| 25 | OKUR | ONKURE THERAPEUTICS INC | $4.19 | -2.56% | 45.49% | -94.88% | $1.8M | 0.74% | −286,725 | −39.3% |
| 26 | LPCN | LIPOCINE INC | $2.05 | -7.24% | -35.33% | -90.86% | $1.8M | 0.71% | +221,616 | NEW |
| 27 | NRXS | NEURAXIS INC | $6.84 | -5.91% | 162.07% | 80.00% | $1.7M | 0.68% | — | HELD |
| 28 | AVTX | AVALO THERAPEUTICS INC | $13.10 | -3.75% | 219.51% | -99.83% | $1.1M | 0.45% | +75,000 | NEW |
| 29 | ANNX | ANNEXON INC | $5.29 | -2.94% | 103.46% | -74.88% | $1.1M | 0.45% | +200,000 | NEW |
| 30 | QQQ | INVESCO QQQ TR | $705.06 | -4.80% | 33.69% | 99.06% | $1.1M | 0.42% | −200,000 | −44.4% |
| 31 | AQST | AQUESTIVE THERAPEUTICS INC | $3.93 | -5.07% | — | — | $1.0M | 0.42% | +250,000 | NEW |
| 32 | SPY | SPDR S&P 500 ETF TR | $737.55 | -2.58% | — | — | $959K | 0.39% | −385,000 | −75.5% |
| 33 | BFRI | BIOFRONTERA INC | $0.94 | -6.03% | — | — | $942K | 0.38% | +23,198 | +2.0% |
| 34 | KURA | KURA ONCOLOGY INC | $8.74 | -0.34% | — | — | $813K | 0.33% | — | HELD |
| 35 | RGNT | REGENTIS BIOMATERIALS LTD | $1.32 | -23.26% | — | — | $768K | 0.31% | — | HELD |
| 36 | VRDN | VIRIDIAN THERAPEUTICS INC | $15.78 | -4.77% | 7.49% | 1.64% | $53K | 0.02% | +263,600 | NEW |
| 37 | AVBP | ARRIVENT BIOPHARMA INC | $30.35 | -8.28% | — | — | — | — | +1,000 | +0.9% |
| 38 | QURE | UNIQURE NV | $26.45 | -5.50% | — | — | — | — | +195,800 | +195.8% |
| 39 | REPL | REPLIMUNE GROUP INC | $9.47 | -4.05% | -8.77% | -71.07% | — | — | −1,410,497 | EXITED |
| 40 | ATYR | ASTRIA THERAPEUTICS INC | $0.47 | -8.38% | — | — | — | — | −1,039,080 | EXITED |
| 41 | CYTK | CYTOKINETICS INC | $71.48 | -1.12% | — | — | — | — | −195,045 | EXITED |
| 42 | BRD1EUR | MIND MEDICINE MINDMED INC | — | — | — | — | — | — | −750,000 | EXITED |
| 43 | OCUL | Ocular Therapeutix, Inc | $8.25 | -6.25% | — | — | — | — | −400,000 | EXITED |
| 44 | AVBP | ARRIVENT BIOPHARMA INC | $30.35 | -8.28% | — | — | — | — | −215,871 | EXITED |
| 45 | AVXL | ANAVEX LIFE SCIENCES CORP | $2.57 | -8.87% | — | — | — | — | −1,168,600 | EXITED |
| 46 | — | SPDR SERIES TRUST | — | — | — | — | — | — | −1,937,600 | EXITED |
| 47 | TRVI | TREVI THERAPEUTICS INC | $13.33 | -4.31% | — | — | — | — | −100,000 | EXITED |
| 48 | — | ISHARES TR | — | — | — | — | — | — | −200,000 | EXITED |
| 49 | GUTS | FRACTYL HEALTH INC | $0.68 | -7.49% | — | — | — | — | −385,731 | EXITED |
| 50 | VSTM | VERASTEM INC | $3.71 | -3.89% | -42.21% | -90.43% | — | — | −268,600 | EXITED |
| 51 | VKTX | VIKING THERAPEUTICS INC | $28.45 | -4.47% | — | — | — | — | −100,000 | EXITED |
| 52 | VTGN | VISTAGEN THERAPEUTICS INC | $0.54 | -6.90% | — | — | — | — | −493,400 | EXITED |
| 53 | RZLT | REZOLUTE INC | $4.25 | -5.76% | — | — | — | — | −263,100 | EXITED |
| 54 | REPL | REPLIMUNE GROUP INC | $9.47 | -4.05% | -8.77% | -71.07% | — | — | −264,700 | EXITED |
Source: SEC EDGAR · accession 0001622627-26-000015. 13F discloses long positions only — shorts, foreign equities, and options are excluded.